Cd38
Preclinical
Cd38 is one of 18 therapeutic programs targeting Kidney. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
21 competitors in Kidney
#DrugCompanyPhaseTrials
1Nulojix
Bristol-Myers SquibbApproved
Prevymis
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Trimethoprim-Sulfamethoxazole
AstellasPhase 3
Libtayo
RegeneronPhase 2
Rayos
RRoxane Laboratories
Phase 2
Rapamune
PPrism Pharmaceuticals
Phase 2
Erbitux
IImclone
Phase 2
Imlifidase
HHansa Biopharma AB
Phase 2
Glucagon
XXeris Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Cd38. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company
- Wwujianyong